Cargando…

COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature

Universal hepatitis B virus (HBV) vaccination has been applied for years in most countries, but HBV infection remains an unresolved public health problem worldwide, with over one-third of the world’s population infected during their lifetime and approximately 248 million hepatitis B surface antigen...

Descripción completa

Detalles Bibliográficos
Autores principales: Sagnelli, Caterina, Montella, Laura, Grimaldi, Pierantonio, Pisaturo, Mariantonietta, Alessio, Loredana, De Pascalis, Stefania, Sagnelli, Evangelista, Coppola, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318431/
https://www.ncbi.nlm.nih.gov/pubmed/35890060
http://dx.doi.org/10.3390/pathogens11070816
_version_ 1784755289169330176
author Sagnelli, Caterina
Montella, Laura
Grimaldi, Pierantonio
Pisaturo, Mariantonietta
Alessio, Loredana
De Pascalis, Stefania
Sagnelli, Evangelista
Coppola, Nicola
author_facet Sagnelli, Caterina
Montella, Laura
Grimaldi, Pierantonio
Pisaturo, Mariantonietta
Alessio, Loredana
De Pascalis, Stefania
Sagnelli, Evangelista
Coppola, Nicola
author_sort Sagnelli, Caterina
collection PubMed
description Universal hepatitis B virus (HBV) vaccination has been applied for years in most countries, but HBV infection remains an unresolved public health problem worldwide, with over one-third of the world’s population infected during their lifetime and approximately 248 million hepatitis B surface antigen (HBsAg) chronic carriers. HBV infection may reactivate with symptomatic and sometimes life-threatening clinical manifestations due to a reduction in the immune response of various origins, due to chemotherapy or immunosuppressive therapy, treatments increasingly practiced worldwide. SARS-CoV-2 and its COVID-19 associated disease have introduced new chances for HBV reactivation due to the use of dexamethasone and tocilizumab to counteract the cytokine storm. This could and should be prevented by accurate screening of HBV serologic markers and adequate pharmacologic prophylaxis. This article describes the case of a patient with COVID-19 who developed HBV reactivation and died of liver failure and analyzes published data on this setting to provide useful information to physicians who manage these patients during the SARS-CoV-2 pandemic.
format Online
Article
Text
id pubmed-9318431
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93184312022-07-27 COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature Sagnelli, Caterina Montella, Laura Grimaldi, Pierantonio Pisaturo, Mariantonietta Alessio, Loredana De Pascalis, Stefania Sagnelli, Evangelista Coppola, Nicola Pathogens Review Universal hepatitis B virus (HBV) vaccination has been applied for years in most countries, but HBV infection remains an unresolved public health problem worldwide, with over one-third of the world’s population infected during their lifetime and approximately 248 million hepatitis B surface antigen (HBsAg) chronic carriers. HBV infection may reactivate with symptomatic and sometimes life-threatening clinical manifestations due to a reduction in the immune response of various origins, due to chemotherapy or immunosuppressive therapy, treatments increasingly practiced worldwide. SARS-CoV-2 and its COVID-19 associated disease have introduced new chances for HBV reactivation due to the use of dexamethasone and tocilizumab to counteract the cytokine storm. This could and should be prevented by accurate screening of HBV serologic markers and adequate pharmacologic prophylaxis. This article describes the case of a patient with COVID-19 who developed HBV reactivation and died of liver failure and analyzes published data on this setting to provide useful information to physicians who manage these patients during the SARS-CoV-2 pandemic. MDPI 2022-07-21 /pmc/articles/PMC9318431/ /pubmed/35890060 http://dx.doi.org/10.3390/pathogens11070816 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sagnelli, Caterina
Montella, Laura
Grimaldi, Pierantonio
Pisaturo, Mariantonietta
Alessio, Loredana
De Pascalis, Stefania
Sagnelli, Evangelista
Coppola, Nicola
COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature
title COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature
title_full COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature
title_fullStr COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature
title_full_unstemmed COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature
title_short COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature
title_sort covid-19 as another trigger for hbv reactivation: clinical case and review of literature
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9318431/
https://www.ncbi.nlm.nih.gov/pubmed/35890060
http://dx.doi.org/10.3390/pathogens11070816
work_keys_str_mv AT sagnellicaterina covid19asanothertriggerforhbvreactivationclinicalcaseandreviewofliterature
AT montellalaura covid19asanothertriggerforhbvreactivationclinicalcaseandreviewofliterature
AT grimaldipierantonio covid19asanothertriggerforhbvreactivationclinicalcaseandreviewofliterature
AT pisaturomariantonietta covid19asanothertriggerforhbvreactivationclinicalcaseandreviewofliterature
AT alessioloredana covid19asanothertriggerforhbvreactivationclinicalcaseandreviewofliterature
AT depascalisstefania covid19asanothertriggerforhbvreactivationclinicalcaseandreviewofliterature
AT sagnellievangelista covid19asanothertriggerforhbvreactivationclinicalcaseandreviewofliterature
AT coppolanicola covid19asanothertriggerforhbvreactivationclinicalcaseandreviewofliterature